Toho Holdings (TSE:8129) Faces Poison Pill Court Fight As Valuation Debate Deepens

3D Investment Partners has taken Toho Holdings (TSE:8129) to the Tokyo District Court, seeking to block a planned poison pill that would dilute its stake as it pursues a modest increase in voting rights.

The legal dispute has landed at a time when Toho Holdings' share price has eased back. The 30 day share price return is 5.29% and the year to date share price return is 15.57% in decline, while longer term total shareholder returns of 41.57% over three years and 122.51% over five years point to gains that contrast with the 24.88% total shareholder return decline over the past year. This suggests recent momentum has faded even as governance questions move into sharper focus.

Spot opportunities where governance and fundamentals may align more cleanly by scanning our hand picked 58 resilient stocks with low risk scores alongside Toho Holdings.

With Toho Holdings down over the past year yet still trading only slightly below analyst targets and an internal value estimate, it is fair to ask whether most of the easy upside is already behind the stock or still ahead.

Preferred P/E of 15.8x for Toho Holdings: Is it justified?

On a simple earnings yardstick, Toho Holdings trades on a P/E of 15.8x, which sits above both its healthcare peers and the wider Japan market averages referenced in analyst data. That points to a market that is willing to pay a premium for the company compared with many local alternatives.

The P/E ratio compares the current share price to earnings per share. For a wholesaler and related healthcare services group like Toho Holdings, it is a quick way for investors to gauge how much of today’s price reflects current profits rather than expectations about future growth or stability.

Analyst data suggests earnings are forecast to grow 2.6% per year and revenue 3% per year, which is slower than the 8.9% earnings and 6.1% revenue growth forecasts for the broader Japan market. Against that backdrop, a P/E of 15.8x that is above the peer average of 13.5x and the Japan healthcare industry average of 13.7x indicates the market is granting Toho Holdings a richer multiple than many comparable companies. However, regression based work used to estimate a fair P/E of 17.6x implies there is room for the valuation to move closer to that level if the company’s profile lines up with the drivers in that model.

Explore the SWS fair ratio for Toho Holdings.

Result: Price-to-Earnings of 15.8x (OVERVALUED)

However, investors also need to weigh risks such as the ongoing legal battle over the poison pill, as well as any future shifts in Toho Holdings' earnings or revenue trends.

Find out about the key risks to this Toho Holdings narrative.

Another view on Toho Holdings using cash flows

The earlier P/E work suggested Toho Holdings looks expensive relative to peers despite a higher fair ratio. A second lens using the SWS DCF model values the shares at ¥4,891.91 versus the current ¥3,957. That points to the stock trading below this cash flow based estimate. Which yardstick do you trust more in a situation like this?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Toho Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 23 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment around Toho Holdings pulled between recent share price pressure and richer valuation signals, it makes sense to check the full picture for yourself and act quickly while the facts are fresh. To see both sides of that picture in one place, take a look at the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Toho Holdings?

If you want to keep sharpening your edge after reviewing Toho Holdings, do not stop here. The next opportunity could be one smart screen away.

• Explore resilient returns by scanning a focused 30 dividend fortresses that may appeal if you value income alongside potential capital growth.
• Search for quality at a reasonable price with our curated 73 high quality undiscovered gems that highlight companies with fundamentals some investors might be overlooking.
• Prioritise stability and financial strength by reviewing a list of solid balance sheet and fundamentals (41 results) that helps you focus on businesses with robust foundations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com